BiotechTube
Zag Bio

Zag Bio

San Francisco, United States· Est.
zagbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11M

Overview

Zag Bio is an early-stage biotech developing a first-in-class platform of thymus-targeted bifunctional antibodies to treat autoimmune diseases. Their technology aims to harness the body's natural process of central tolerance by delivering specific self-antigens to the thymus, thereby generating antigen-specific regulatory T cells (Tregs) that can home to diseased tissues and suppress inflammation. This approach promises a precise, potent, and potentially durable therapeutic effect without the broad immunosuppression associated with current treatments. The company is currently in the preclinical stage, building its pipeline and platform.

Autoimmune Diseases

Technology Platform

Proprietary platform for developing thymus-targeted, bifunctional antibodies. These antibodies are engineered to deliver specific self-antigens to antigen-presenting cells (APCs) within the thymus, aiming to induce central immune tolerance by generating antigen-specific regulatory T cells (Tregs) and deleting autoreactive T cells.

Funding History

1
Total raised:$11M
Seed$11M

Opportunities

The global autoimmune disease market is large and growing, with a major unmet need for therapies that are precise, durable, and not broadly immunosuppressive.
Zag Bio's platform, if successful, could address this need and be applied across a wide range of autoimmune conditions, creating a pipeline-in-a-product opportunity.
Demonstrating proof-of-concept in humans would likely attract significant partnership interest from large pharmaceutical companies.

Risk Factors

The core scientific approach of pharmacologically targeting the thymus is novel and high-risk, with unproven translatability to humans.
As a preclinical, private company, Zag Bio faces significant development, regulatory, and financing risks.
It also operates in a competitive landscape with other companies pursuing antigen-specific tolerance through different modalities.

Competitive Landscape

Zag Bio competes in the broader field of antigen-specific tolerance therapies. Direct competitors include companies developing peptide-based tolerogenic vaccines (e.g., Anokion, Cour Pharmaceuticals) and engineered Treg cell therapies. Indirect competitors are all providers of broad immunosuppressive and immunomodulatory drugs for autoimmune diseases. Zag Bio's differentiation is its specific focus on thymic delivery via bifunctional antibodies.

More companies in United States →